Literature DB >> 16682138

Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy.

Caroline Gaudy-Marqueste1, Jean-Marie Regis, Xavier Muracciole, Renaud Laurans, Marie-Aleth Richard, Jean-Jacques Bonerandi, Jean-Jacques Grob.   

Abstract

PURPOSE: To assess retrospectively a strategy that uses Gamma-Knife radiosurgery (GKR) in the management of patients with brain metastases (BMs) of malignant melanoma (MM).
METHODS: GKR without whole-brain radiotherapy (WBRT) was performed for patients with Karnofsky Performance Status (KPS) of 60 or above who harbored 1 to 4 BMs of 30 mm or less and was repeated as often as needed. Survival was assessed in the whole population, whereas local-control rates were assessed for patients with follow-up longer than 3 months.
RESULTS: A total of 221 BMs were treated in 106 patients; 61.3% had a single BM. Median survival from the time of GKR was 5.09 months. Control rate of treated BMs was 83.7%, with 14% of complete response (14 BMs), 42% of partial response (41 BMs), and 43% of stabilization (43 BMs). In multivariate analysis, survival prognosis factors retained were KPS greater than 80, cortical or subcortical location, and Score Index for Radiosurgery (SIR) greater than 6. On the basis of KPS, BM location, and age, a score called MM-GKR, predictive of survival in our population, was defined.
CONCLUSION: Gamma-Knife radiosurgery provides a surgery-like ability to obtain control of a solitary BM and could be consider as an alternative treatment to the combination of GKR+WBRT as a palliative strategy. MM-GKR classification is more adapted to MM patients than are SIR, RPA and Brain Score for Brain Metastasis.

Entities:  

Mesh:

Year:  2006        PMID: 16682138     DOI: 10.1016/j.ijrobp.2006.01.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Total target volume is a better predictor of whole brain dose from gamma stereotactic radiosurgery than the number, shape, or location of the lesions.

Authors:  Ganesh Narayanasamy; Adam Smith; Emily Van Meter; Ronald McGarry; Janelle A Molloy
Journal:  Med Phys       Date:  2013-09       Impact factor: 4.071

2.  Hypofractionated stereotactic radiotherapy for oligometastases in the brain: a single-institution experience.

Authors:  Marcello Marchetti; Ida Milanesi; Chiara Falcone; Michela De Santis; Luisa Fumagalli; Lorenzo Brait; Livia Bianchi; Laura Fariselli
Journal:  Neurol Sci       Date:  2011-01-14       Impact factor: 3.307

3.  Whole-brain radiotherapy in patients with brain metastases from melanoma.

Authors:  Macarena de la Fuente; Kathryn Beal; Richard Carvajal; Thomas J Kaley
Journal:  CNS Oncol       Date:  2014-11

4.  Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.

Authors:  Amparo Wolf; Sayyad Zia; Rashika Verma; Anna Pavlick; Melissa Wilson; John G Golfinos; Joshua S Silverman; Douglas Kondziolka
Journal:  J Neurooncol       Date:  2016-02-06       Impact factor: 4.130

5.  Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

Authors:  Maria J Sambade; Eldon C Peters; Nancy E Thomas; William K Kaufmann; Randall J Kimple; Janiel M Shields
Journal:  Radiother Oncol       Date:  2011-02-04       Impact factor: 6.280

Review 6.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

Review 7.  Current treatment options of brain metastases and outcomes in patients with malignant melanoma.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

Review 8.  Radiosurgery for metastatic brain tumors.

Authors:  Toru Serizawa
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

Review 9.  [Melanoma brain metastases : Treatment options].

Authors:  R Rauschenberg; G Tabatabai; E G C Troost; M Garzarolli; S Beissert; F Meier
Journal:  Hautarzt       Date:  2016-07       Impact factor: 0.751

Review 10.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.